July 14th 2023 Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States https://www.businesswire.com/news/home/20230706685508/en/Shorla-Oncology-Announces-Licensing-Agreement-and-Strategic-Partnership-for-Rights-to-Market-Chemotherapy-Drug-PIP-101-in-the-United-States
Mid-West Building Better Business eventMay 31st 2023Read More Mid-West Building Better Business event
Shorla Oncology at BioEquity Europe 2023 in DublinMay 16th 2023Read More Shorla Oncology at BioEquity Europe 2023 in Dublin
Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine InjectionMay 16th 2023Read More Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection
Shorla Oncology will be attending Asembia’s ASX Summit in Las VegasApril 17th 2023Read More Shorla Oncology will be attending Asembia’s ASX Summit in Las Vegas
FDA Approves Nelarabine Injection for T-cell Leukemia and LymphomaMarch 27th 2023Read More FDA Approves Nelarabine Injection for T-cell Leukemia and Lymphoma
Our CEO to speak at BioEquity: Europe 2023 in Dublin on May 14-16, 2023March 23rd 2023Read More Our CEO to speak at BioEquity: Europe 2023 in Dublin on May 14-16, 2023
